Key result
Transcatheter therapies for mitral regurgitation are anticipated to become available for clinical use in selected patients, following the dissemination model of transcatheter aortic valve replacement.
The article anticipates the clinical availability and thoughtful dissemination of transcatheter therapies for mitral regurgitation, following the model of TAVR.
Transcatheter aortic valve replacement (TAVR) has transformed the care of patients with aortic stenosis. The dissemination of this technology after its approval in the United States in the wake of a pivotal randomized trial1,2 has thus far proceeded in a thoughtful and circumspect manner, guided by a coalition of stakeholders dedicated to the delivery of high-quality, patient-centered care. It is anticipated that a number of transcatheter therapies for mitral regurgitation (MR) will also become available for clinical use in selected patients.
No takes yet. Share an insight, caveat, or question.
O’Gara et al. (2013) conducted an editorial in Mitral regurgitation. Transcatheter therapies was evaluated. Transcatheter therapies for mitral regurgitation are anticipated to become available for clinical use in selected patients, following the dissemination model of transcatheter aortic valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: